ArticleACS omega2026
Nasal-to-Brain ROS-Responsive Diselenide-Bridged Graphene Nanogel for Targeted Ischemic Stroke Therapy via Microglial Modulation.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Secondary oxidative stress and neuroinflammation following ischemic stroke exacerbate neuronal death, blood-brain barrier (BBB) disruption, and neurological deficits. To address these intertwined injury cascades, we developed a diselenide-bridged hyaluronic acid/graphene oxide quantum dot nanogel (DRC@GOQD-HA-Se) for intranasal delivery of Dauricinea bisbenzylisoquinoline alkaloid with antioxidant and immunomodulatory properties. The diselenide (Se-Se) cross-links confer reactive oxygen species (ROS)-triggered degradation and on-demand drug release, while the HA shell enhances microglial targeting via CD44 receptors and facilitates BBB bypass via nose-to-brain transport.DRC@GOQD-HA-Se directly scavenged multiple ROS, eliminating ∼136 ± 10 U/mL of •OH and ∼80 ± 7 U/mL of O
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.